KUALA LUMPUR, Dec 2 (Bernama) -- Unum Therapeutics, a company developing a universal cellular immunotherapy to treat multiple cancers, announced today that recruitment has begun in the first clinical trial of the ATTCK20 therapy. The Phase I study will examine the feasibility, safety and potential efficacy of infusing the ATTCK20 combination therapy in patients with B-cell malignancies and persistent disease following standard therapy. The clinical program commences shortly after the company's official launch in October 2014.
For the full text, click here.
For the full text, click here.
No comments:
Post a Comment